KCT0003598
Active, not recruiting
未知
Does measurement of fecal calprotectin levels help distinguish intestinal tuberculosis, Crohn’s disease, and ulcerative colitis?
Eulji University Hospital0 sites30 target enrollmentTBD
ConditionsDiseases of the digestive system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the digestive system
- Sponsor
- Eulji University Hospital
- Enrollment
- 30
- Status
- Active, not recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •We retrospectively reviewed the medical records of over 20 years old patients with renal tuberculosis, Crohn 's disease, and ulcerative colitis treated with calprotectin in the stool.
Exclusion Criteria
- •Under 20 years
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Relevance of fecal calprotectin as a biomarker to predict the outcome of Adalimumab therapy in Ulcerative Colitis patients.lcerative ColitisJPRN-UMIN000022104Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine54
Recruiting
Not Applicable
Study on the usefulness of fecal calprotectin in ulcerative colitis and the relevance of other biomarkerslcerative colitisJPRN-UMIN000052832Ehime University150
Completed
Not Applicable
Can fecal calprotectin be a predictive marker for refractoriness in patients with ulcerative colitis ?lcerative colitisJPRN-UMIN000024146Showa University, School of Medicine100
Completed
Not Applicable
The value of faecal calprotectin (CPT) in monitoring the response to treatment of patients with inflammatory bowel diseaseInflammatory bowel diseaseDigestive SystemCrohn's disease [regional enteritis]ISRCTN81965907Department of Health (UK)80
Recruiting
Not Applicable
The use of fecal calprotectin in detecting immunotherapy induced colitis and feasibility for the use of immunohistochemical markers in patients receiving checkpoint inhibitors’- a pilot studycolitisNL-OMON25248KI-AV50